Moody Lynn & Lieberson LLC Sells 3,172 Shares of Johnson & Johnson (JNJ)

Moody Lynn & Lieberson LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the second quarter, HoldingsChannel.com reports. The firm owned 108,823 shares of the company’s stock after selling 3,172 shares during the quarter. Johnson & Johnson comprises 1.6% of Moody Lynn & Lieberson LLC’s holdings, making the stock its 24th largest position. Moody Lynn & Lieberson LLC’s holdings in Johnson & Johnson were worth $13,205,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after buying an additional 7,853,141 shares during the last quarter. Boston Partners grew its stake in shares of Johnson & Johnson by 68.7% during the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after buying an additional 5,207,124 shares during the last quarter. Cornerstone Wealth Management LLC grew its stake in shares of Johnson & Johnson by 10,307.6% during the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after buying an additional 2,473,105 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after buying an additional 1,833,622 shares during the last quarter. Finally, Summit Trail Advisors LLC grew its stake in shares of Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after buying an additional 1,752,841 shares during the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.

In related news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by corporate insiders.

A number of research firms have recently commented on JNJ. Credit Suisse Group upped their target price on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday. Raymond James upped their target price on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $141.54.

Shares of NYSE:JNJ opened at $139.50 on Friday. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a market capitalization of $370.70 billion, a P/E ratio of 19.11, a PEG ratio of 2.19 and a beta of 0.70. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The company had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. Johnson & Johnson’s revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be paid a $0.90 dividend. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.58%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Hedge Funds

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply